3 reports

  • 8. Global Renal Cell Carcinoma Drugs Market - Company Wise Pipeline Analysis
  • dalantercept (Acceleron)

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. The global renal cell carcinoma drugs market is anticipated to cross US$ 4.3 Billion mark by 2021. There are many factors, like smoking, hypertension, unhealthy eating...

  • Cancer
  • Renal Cancer
  • Targeted Therapy
  • Exelixis, Inc.
  • TRACON Pharmaceuticals, Inc.
  • Mar 14, 2016: Tracon Pharmaceuticals Initiates Phase 1B Study Of TRC105 In Patients With Lung Cancer
  • TRACON Pharma Raises USD36 Million in IPO

Summary TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company that develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases.The company offers pipeline products such as TRC105, TRC102, TRC253, TRC694, and TRC205. Its lead product TRC105, is an...

  • Cancer
  • Pharmaceutical
  • United States
  • Company
  • TRACON Pharmaceuticals, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Trials conducted by companies in Phase III, Phase II and Phase I stand at ##, ## and ## respectively.

  • Cancer
  • Pathology
  • Therapy
  • World
  • TRACON Pharmaceuticals, Inc.